Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Tiziana Life Sciences' foralumab reduces side effects of discontinuing GLP-1 agonists
10:09am, Friday, 10'th Jan 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its intranasal anti-CD3 monoclonal antibody, foralumab, has demonstrated the ability to mitigate the side effects associated with the discontinua
GLP-1 makers could be under pressure in 2025
07:29pm, Monday, 06'th Jan 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk what is next for the obesity drug makers in 2025.
Cramer's Mad Dash: Cornell report on GLP-1s shows decrease in consumption of savory snacks
11:19am, Friday, 03'rd Jan 2025
CNBC's Jim Cramer reports on a study from Cornell and its impact on the stock market.
Should You Buy the Dip in Novo Nordisk Stock Right Now?
08:30am, Thursday, 02'nd Jan 2025
The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and chron
Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst
09:00am, Sunday, 29'th Dec 2024
Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets c
Novo Nordisk Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory Deal
04:21pm, Thursday, 19'th Dec 2024
Novo has handed Wolff one of the most complex jobs in all of pharmaceuticals.
Viking Therapeutics: Holiday Gift
10:30am, Thursday, 19'th Dec 2024
Viking Therapeutics has seen a significant drop, losing 50% in value since late October, despite positive news and promising GLP-1 drug developments. The biotech's oral GLP-1 candidate VK2735 showed i
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
09:15am, Thursday, 19'th Dec 2024
BALTIMORE--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapie
Lexaria's Registered GLP-1 Study #4 Begins Dosing
09:05am, Thursday, 19'th Dec 2024
Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "C
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
08:30am, Thursday, 19'th Dec 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, to
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
10:38am, Wednesday, 18'th Dec 2024
Recent sales of a little-known stock, Madrigal Pharmaceuticals NASDAQ: MDGL, could bode well for Novo Nordisk A/S NYSE: NVO. The pharma industry giant has seen explosive sales growth for its GLP-1 ago
BEIJING and BRIDGEWATER, N.J. , Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
08:50am, Monday, 16'th Dec 2024
Successful Completion of All Planned Implants in GLP Study enVVe Delivery System Demonstrates Consistent Performance Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP
Conagra Brands Introduces Badges on Select Healthy Choice Products, Leading Consumers to GLP-1-Friendly Options
10:28am, Thursday, 12'th Dec 2024
CHICAGO , Dec. 12, 2024 /PRNewswire/ -- With the rising popularity of GLP-1 medications among Americans for diabetes and weight management, Conagra Brands is proud to announce a first-of-its-kind init
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
09:10am, Monday, 09'th Dec 2024
Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide KELOWNA, BC / ACCESSWIRE / December 9, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)
